Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Central Nervous System Drugs Market Briefing 2017: Market is Expected to Reach Around $82 Billion in 2020 - Research and Markets

Research and Markets
Posted on: 03 Jan 18

The "Central Nervous System Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global central nervous system drugs market is expected to reach around $82 billion in 2020

Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions.

The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord's ability to function is affected, hence affecting the body.

Wearables To Improve R&D - Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson's disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%.

For instance, in 2016, Michael J. Fox Foundation for Parkinson's Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson's disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer's disease research.

Scope:

  • Markets Covered: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Shire Plc.
  • UCB S.A.
  • Eli Lilly And Company
  • Sanofi S.A.
  • Daiichi Sankyo Company Limited

For more information about this report visit https://www.researchandmarkets.com/research/hjxmkr/global_central?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180103005988/en/

Business Wire
www.businesswire.com

Last updated on: 03/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.